Boosting Treatment for Newly Diagnosed Diffuse Large B-cell Lymphoma Patients

Recruiting · Phase 3 · Diffuse Large B-cell Lymphoma (DLBCL) · 13 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This study is looking at how well an experimental drug called odronextamab works when combined with chemotherapy for patients with Diffuse Large B-cell Lymphoma (DLBCL) who have not been treated before. The goal is to see if this combination is better and safer than the standard treatment using rituximab and chemotherapy. This trial also explores the side effects of the study drug and how it affects patients' daily lives.

This is a Phase 3 trial, which means it is looking at how well the treatments work and how safe they are. The trial is FDA-regulated and aims to include about 904 participants.

Who can join

Adults aged 18 and older can join the study if they have untreated DLBCL or DLBCL that has come back after treatment. They should have measurable disease and meet certain health criteria. Some conditions may prevent participation, like having certain infections or other cancers. The trial team will confirm who is eligible to join.

Condition

Diffuse Large B-cell Lymphoma (DLBCL)

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Participants will be randomly placed into one of two groups. One group will receive the new drug odronextamab along with standard chemotherapy (called Odro-CHOP). The other group will receive rituximab with chemotherapy (called R-CHOP). Everyone will get treatment, but the specific group they are in will be decided by chance.